Skip to main content
SpringerLink
Log in

Endoscopic and laparoscopic ultrasonography used to predict tumor staging and improve therapeutic decisions for upper gastrointestinal tract cancer

  • Letter
  • Published:
Surgical Endoscopy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mortensen MB, Fristrup C, Ainsworth A, Nielsen HO, Pless T, Hovendal C (2011) Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer. Surg Endosc 25:804–812

    Article  PubMed  Google Scholar 

  2. Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18:12–15

    Article  PubMed  Google Scholar 

  3. Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10:247–250

    Article  PubMed  Google Scholar 

  4. Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681

    Article  PubMed  Google Scholar 

  5. Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Device 7:723–726

    Article  CAS  Google Scholar 

  6. Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7:347–350

    Article  CAS  Google Scholar 

  7. Lander ES (2011) Initial impact of the sequencing of the human genome. Nature 470:187–197

    Article  PubMed  CAS  Google Scholar 

  8. Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798

    Article  Google Scholar 

  9. Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695

    Article  PubMed  Google Scholar 

  10. Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253–255

    Article  PubMed  CAS  Google Scholar 

  11. Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59–62.

    Article  PubMed  Google Scholar 

  12. Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943

    PubMed  Google Scholar 

  13. Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773

    Article  PubMed  Google Scholar 

  14. Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068

    Article  PubMed  Google Scholar 

  15. Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996

    Google Scholar 

  16. Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128

    Article  PubMed  CAS  Google Scholar 

  17. Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545

    Article  PubMed  CAS  Google Scholar 

  18. Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586

    Article  PubMed  Google Scholar 

  19. Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043

    Article  PubMed  CAS  Google Scholar 

  20. Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11(2):81–92

    Article  PubMed  CAS  Google Scholar 

  21. Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126

    Article  PubMed  CAS  Google Scholar 

  22. Roukos DH (2011) Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices 8(4):409–413

    Article  PubMed  Google Scholar 

  23. Roukos DH (2011) Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics 12(5):695–698

    Article  PubMed  Google Scholar 

Download references

Disclosure

Christof Hottenrott has no conflicts of interest or financial ties to disclose.

Author information

Authors and Affiliations

  1. Chirurgische Klinik, St. Elisabethenkrankenhaus, Ginnheimer Straße 3, 60487, Frankfurt, Germany

    Christof Hottenrott

Authors
  1. Christof Hottenrott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christof Hottenrott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hottenrott, C. Endoscopic and laparoscopic ultrasonography used to predict tumor staging and improve therapeutic decisions for upper gastrointestinal tract cancer. Surg Endosc 26, 280–281 (2012). https://doi.org/10.1007/s00464-011-1847-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00464-011-1847-2

Keywords

Search

Navigation